Intravitreal Bevacizumab for Diabetic Macular Edema

Isfahan Ophthalmology Research Center

Overview

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Study Type

INTERVENTIONAL

Conditions

Macular Edema Diabetic Retinopathy

Interventions

BevacizumabDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes mellitus * Clinically significant macular edema * Possibility of performing macular OCT * Consent of patient for inclusion in the study Exclusion Criteria: * History of macular photocoagulation in less than 6 months of inclusion in the study * Necessity of surgical intervention * Rejection of the remaining in the study by patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.